[go: up one dir, main page]

PE20191785A1 - Composiciones y metodos que involucran moleculas probioticas - Google Patents

Composiciones y metodos que involucran moleculas probioticas

Info

Publication number
PE20191785A1
PE20191785A1 PE2019001881A PE2019001881A PE20191785A1 PE 20191785 A1 PE20191785 A1 PE 20191785A1 PE 2019001881 A PE2019001881 A PE 2019001881A PE 2019001881 A PE2019001881 A PE 2019001881A PE 20191785 A1 PE20191785 A1 PE 20191785A1
Authority
PE
Peru
Prior art keywords
amino acid
peptide
compositions
less
acid residues
Prior art date
Application number
PE2019001881A
Other languages
English (en)
Inventor
Monica Angela Cella
Sarah M Curtis
Jonathon Patrick Roepke
Original Assignee
Microsintesis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microsintesis Inc filed Critical Microsintesis Inc
Publication of PE20191785A1 publication Critical patent/PE20191785A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/195—Proteins from microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a un peptido que comprende la secuencia de aminoacidos MALPPK, caracterizado porque el peptido tiene menos de 19 residuos de aminoacidos; CVLPPK, menos de 68 residuos de aminoacidos; HLLPLP, menos de 9 residuos de aminoacidos. En donde dicho peptido esta caracterizado porque esta derivado de bacterias probioticas, tales como Lactobacillus, Lactococcus, entre otros. Ademas, estas peptidos se combinan con uno o mas antivirales, una fuente de azucar, productos alimenticios, bebidas, suplementos nutricionales, medicamentos y similares. Estos peptidos son utiles para prevenir y/o tratar una infeccion no enterica, y para reducir su virulencia.
PE2019001881A 2017-03-16 2018-03-16 Composiciones y metodos que involucran moleculas probioticas PE20191785A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472047P 2017-03-16 2017-03-16
PCT/CA2018/050319 WO2018165764A1 (en) 2017-03-16 2018-03-16 Compositions and methods involving probiotic molecules

Publications (1)

Publication Number Publication Date
PE20191785A1 true PE20191785A1 (es) 2019-12-24

Family

ID=63522209

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001881A PE20191785A1 (es) 2017-03-16 2018-03-16 Composiciones y metodos que involucran moleculas probioticas

Country Status (17)

Country Link
US (2) US20200016290A1 (es)
EP (1) EP3596103A4 (es)
JP (1) JP7252145B2 (es)
KR (1) KR20190141667A (es)
CN (1) CN110621689B (es)
AU (2) AU2018233588A1 (es)
BR (1) BR112019019255A2 (es)
CA (1) CA3056718A1 (es)
CL (1) CL2019002641A1 (es)
EA (1) EA201992175A1 (es)
MA (1) MA52150A (es)
MX (1) MX2019011060A (es)
NZ (1) NZ758166A (es)
PE (1) PE20191785A1 (es)
PH (1) PH12019502341A1 (es)
SG (1) SG11201909602TA (es)
WO (1) WO2018165764A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201909606RA (en) 2017-03-16 2019-11-28 Microsintesis Inc Probiotic molecules for reducing pathogen virulence
KR102135195B1 (ko) * 2018-10-08 2020-07-17 아주대학교산학협력단 테트라제노코커스 할로필러스를 포함하는 베체트병 또는 헤르페스 바이러스 감염증의 예방 또는 치료용 조성물
AU2020299061A1 (en) * 2019-07-02 2022-02-10 Microsintesis Inc. Quorum-sensing inhibitors and/or postbiotic metabolites and related methods
CN112980712A (zh) * 2019-12-14 2021-06-18 山东大学 一种调节高原人群情绪及肠道菌群稳定的微生物组合物及其应用
CN114591879B (zh) * 2022-05-11 2022-12-06 中国农业大学 一种抑制幽门螺杆菌的发酵乳杆菌及其应用
KR102551065B1 (ko) * 2022-05-12 2023-07-03 중앙대학교 산학협력단 김치로부터 유래된 LAB(lactic acid bacteria)을 유효성분으로 포함하는 항-바이오필름 조성물
WO2024097250A1 (en) * 2022-10-31 2024-05-10 The Trustees Of Columbia University In The City Of New York Polymeric carrier for probiotics
KR20240121187A (ko) * 2023-01-31 2024-08-08 한국생명공학연구원 항-헬리코박터 파일로리 활성을 갖는 신규 균주 및 이의 용도
CN117815160B (zh) * 2023-11-08 2024-05-28 首都医科大学附属北京潞河医院 一种黄芪散饮片的制备及其在治疗慢性肾功能不全中的应用
CN117660253B (zh) * 2023-12-10 2024-11-01 石河子大学 一种鼠李糖乳酪杆菌fmbl l23004 cnn、酸奶发酵剂、酸奶及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69024400T2 (de) * 1989-04-28 1996-06-27 Takara Shuzo Co Dem menschlichen Calpastatin ähnliches Polypeptid
FR2686085B1 (fr) * 1992-01-10 1995-08-04 Agronomique Inst Nat Rech Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
WO1994018832A1 (en) * 1993-02-26 1994-09-01 Dana-Farber Cancer Institute, Inc. Cd4 mediated modulation of lipid kinases
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
ES2381118T3 (es) * 2004-12-23 2012-05-23 Campina Nederland Holding B.V. Hidrolizado de proteínas enriquecido en péptidos de inhibición de DPP-IV y su uso
PL2236608T3 (pl) * 2005-10-04 2017-06-30 Soligenix, Inc. Nowe peptydy do leczenia i profilaktyki zaburzeń immuno-zależnych w tym do leczenia i profilaktyki zakażenia przez modulację odporności wrodzonej
WO2007057872A2 (en) * 2005-11-21 2007-05-24 Teagasc-National Diary Products Research Centre Casein-derived antimicrobial peptides and lactobacillus strains that produce them
US8431528B2 (en) * 2008-05-16 2013-04-30 University Of Maryland, Baltimore Antibacterial Lactobacillus GG peptides and methods of use
ES2908705T3 (es) 2008-06-27 2022-05-03 Microsintesis Inc Análisis de moléculas de interferencia de la señal de lactobacillus acidophilus La-5
US8758765B2 (en) * 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
GB201001602D0 (en) * 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof
EP2550529B1 (en) * 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
SG11201500111VA (en) * 2012-08-29 2015-03-30 Agency Science Tech & Res Peptides and uses thereof
WO2014033281A1 (en) * 2012-08-31 2014-03-06 Westfaelische Wilhelms-Universitaet Muenster Methods and peptides for preventing and treating a bcr-abl and a c-abl associated disease
AU2014262127B2 (en) * 2013-05-01 2019-05-02 Neoculi Pty Ltd Methods for treating bacterial infections
US9861666B2 (en) * 2013-08-12 2018-01-09 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules
JP6262694B2 (ja) * 2014-08-18 2018-01-17 森永乳業株式会社 プロリルオリゴペプチダーゼ阻害剤
WO2016172722A1 (en) * 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
SG11201909606RA (en) * 2017-03-16 2019-11-28 Microsintesis Inc Probiotic molecules for reducing pathogen virulence
AU2020299061A1 (en) * 2019-07-02 2022-02-10 Microsintesis Inc. Quorum-sensing inhibitors and/or postbiotic metabolites and related methods

Also Published As

Publication number Publication date
AU2022202600A1 (en) 2022-05-12
SG11201909602TA (en) 2019-11-28
WO2018165764A1 (en) 2018-09-20
JP7252145B2 (ja) 2023-04-04
EP3596103A4 (en) 2021-01-20
KR20190141667A (ko) 2019-12-24
AU2022202600B2 (en) 2024-01-04
CL2019002641A1 (es) 2020-05-15
MA52150A (fr) 2020-01-22
JP2020510095A (ja) 2020-04-02
CN110621689B (zh) 2024-04-16
NZ758166A (en) 2024-12-20
EA201992175A1 (ru) 2020-03-05
CA3056718A1 (en) 2018-09-20
US20200016290A1 (en) 2020-01-16
PH12019502341A1 (en) 2020-10-12
MX2019011060A (es) 2019-12-09
BR112019019255A2 (pt) 2020-04-14
US20240016970A1 (en) 2024-01-18
AU2018233588A1 (en) 2019-10-31
EP3596103A1 (en) 2020-01-22
CN110621689A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
PE20191785A1 (es) Composiciones y metodos que involucran moleculas probioticas
PE20191783A1 (es) Moleculas probioticas para reducir virulencia patogena
MX350325B (es) Bacteria para usarse como un probiotico para aplicaciones nutricionales y medicas.
BR132020021160E2 (pt) composição compreendendo um fermentado de bactéria probiótica lactobacillus paracasei cba l74 e uso do mesmo
PH12013501892A1 (en) Nutritional compositions including branched chain fatty acids for wound healing
NZ741028A (en) Novel lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders
EA202090948A1 (ru) Иммуномодуляция
MX2017016283A (es) Lactobacillus paracasei para la produccion de acido linoleico conjugado, preparaciones nutricionales y farmaceuticas que lo contienen y sus usos.
MY197201A (en) Novel probiotics bifidobacteria strains
MY187060A (en) Bifidobacteria as probiotic foundation species of gut microbiota
MX2022011742A (es) Composicion nutritiva para el entorno gastrointestinal para proporcionar microbioma y perfil metabolico mejorados.
CN107405369A8 (zh) 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法
MX383749B (es) Cepas probioticas con capacidad de absorber colesterol, métodos y usos de las mismas
EP3799722A3 (en) Composition comprising commensal probiotic and prebiotic
BR112017014580A2 (pt) método para obter um isolado peptídico a partir de uma biomassa de microalgas enriquecidas com proteína
BR112015028164A2 (pt) probióticos e métodos de uso
BR112017006969A2 (pt) peptídeo derivado de hsp70, composição farmacêutica para o tratamento ou a prevenção de câncer usando o mesmo, indutor de imunidade e método de produção de célula apresentadora de antígeno
EP4470625A3 (en) A pharmaceutical composition comprising a combination of probiotic and prebiotic to treat stunting
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
MX371444B (es) Metodo para inducir saciedad.
MX2020001501A (es) Streptococcus australis como bioterapeuticos.
AU2018275270A1 (en) Peptide PAC1 antagonists
AR119220A1 (es) Composiciones y métodos de tratamiento de un estado mediado por th2 usando prevotella
BR112018071076A2 (pt) composições, método para a preparação de um produto lácteo fermentado e uso da composição
AR100185A1 (es) Una composición sinérgica que comprende una mezcla de bacterias del género lactobacillus y propionobacterium particularmente útil para reducir o eliminar la contaminación de patógenos en harina de soja y sus derivados, métodos y usos